Clinical Trials Logo

Vasomotor Symptoms clinical trials

View clinical trials related to Vasomotor Symptoms.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03122301 Terminated - Hot Flashes Clinical Trials

Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer

Start date: June 1, 2017
Phase: Phase 2
Study type: Interventional

Vasomotor symptoms (hot flashes, night sweats, VMS) affect up to 65% of breast cancer survivors and negatively impact their quality of life. VMS in Hispanic women are significantly more severe as compared to non-Hispanic Caucasian women. Few effective treatments for VMS are available, especially in the underserved Hispanic and Spanish-speaking populations which is problematic, as Hispanics will comprise 20% of the U.S. population by 2025. Stellate ganglion nerve block (SGB) with local anesthetic, previously performed for chronic pain indications, has shown promise as a potential treatment for menopausal women with VMS in previous clinical trials, but has not been investigated in Hispanic or Spanish-Speaking women with breast cancer in a controlled study.

NCT ID: NCT02653417 Terminated - Hot Flashes Clinical Trials

Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms

Start date: December 2015
Phase: Phase 2
Study type: Interventional

The primary objective of this study was to determine the clinical safety of RAD1901 and to evaluate whether RAD1901 reduced the frequency and severity of moderate to severe vasomotor symptoms (VMS; "hot flashes") in postmenopausal women.

NCT ID: NCT01353963 Terminated - Clinical trials for Major Depressive Disorder

Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients

Start date: March 2012
Phase: Phase 4
Study type: Observational

This is a non-interventional study to review safety data on administration of desvenlafaxine succinate among Filipino patients with MDD and VMS per usual clinical practice within the first three years post commercial distribution.